Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Kamada, Ltd.

Clinical trials sponsored by Kamada, Ltd., explained in plain language.

Kamada, Ltd. KMDA NASDAQ

A biopharmaceutical company developing plasma-derived therapies.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Can an inhaled protein save lungs in Alpha-1? new trial aims to find out

Disease control Terminated

This study tests whether inhaling alpha-1 antitrypsin (AAT) daily can slow lung function loss in people with Alpha-1 deficiency and moderate-to-severe lung disease. 220 adults will receive either the drug or a placebo for two years, then all will receive the drug for two more yea…

Phase: PHASE3 • Sponsor: Kamada, Ltd. • Aim: Disease control

Last updated Aug 14, 2026 00:00 UTC